T cell activation upon exposure to patient-derived tumor tissue: A functional assay to select patients for adoptive T cell therapy

Journal of Immunological Methods

Volumn 359, Issue 1-2, 2010, Pages 11-20

  Schroten, Caroline ^a   Kraaij, Robert ^a   Veldhoven, Joke L M ^a   Berrevoets, Cor A ^a   den Bakker, Michael A ^a   Ma, Qiangzhong ^b   Sadelain, Michel ^c   Bangma, Chris H ^a   Willemsen, Ralph A ^a   Debets, Reno ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chimeric antibody based receptor (CAR); Gene modified T cells; NFAT reporter gene assay; Prostate cancer; T cell therapy

Indexed keywords

ANTIGEN; CARBONATE DEHYDRATASE IX; CHIMERIC ANTIBODY; CHIMERIC ANTIBODY BASED RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE T LYMPHOCYTE THERAPY; ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER TISSUE; CELL ASSAY; CELL THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEUKEMIA CELL LINE; PATIENT SELECTION; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; GENETIC ENGINEERING; HUMANS; JURKAT CELLS; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; PATIENT SELECTION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 77954386735     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.04.006     Document Type: Article

References (31)

1. Aarnoudse C.A., Kruse M., Konopitzky R., Brouwenstijn N., Schrier P.I. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning. Int. J. Cancer 2002, 99(1):7.
2. Bostwick D.G., Pacelli A., Blute M., Roche P., Murphy G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82(11):2256.
3. Emtage P.C., Lo A.S., Gomes E.M., Liu D.L., Gonzalo-Daganzo R.M., Junghans R.P. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin. Cancer Res. 2008, 14(24):8112.
4. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(2):720.
5. Gong M.C., Latouche J.B., Krause A., Heston W.D., Bander N.H., Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999, 1(2):123.
6. Hanks G.E., Dawson A.K. The role of external beam radiation therapy after prostatectomy for prostate cancer. Cancer 1986, 58(11):2406.
7. Henry R.Y., O'Mahony D. Treatment of prostate cancer. J. Clin. Pharm. Ther. 1999, 24(2):93.
8. Hombach A., Wieczarkowiecz A., Marquardt T., Heuser C., Usai L., Pohl C., Seliger B., Abken H. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 2001, 167(11):6123.
9. Hooijberg E., Bakker A.Q., Ruizendaal J.J., Spits H. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 2000, 96(2):459.
10. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., Heston W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 1994, 54(7):1807.
11. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., Chen C.C., Yang J.C., Rosenberg S.A., Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12(20 Pt 1):6106.
12. Kraaij R., van Rijswijk A.L., Oomen M.H., Haisma H.J., Bangma C.H. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate 2005, 62(3):253.
13. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., Gratama J.W., Stoter G., Oosterwijk E. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 2006, 24(13):e20.
14. Lamers C.H., Willemsen R.A., van Elzakker P., van Krimpen B.A., Gratama J.W., Debets R. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer. Cancer Gene Ther. 2006, 13(5):503.
15. Lamers C.H., Langeveld S.C., Groot-van Ruijven C.M., Debets R., Sleijfer S., Gratama J.W. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol. Immunother. 2007, 56(12):1875.
16. Liao S.Y., Aurelio O.N., Jan K., Zavada J., Stanbridge E.J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997, 57(14):2827.
17. Liu H., Moy P., Kim S., Xia Y., Rajasekaran A., Navarro V., Knudsen B., Bander N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997, 57(17):3629.
18. Ma Q., Safar M., Holmes E., Wang Y., Boynton A.L., Junghans R.P. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004, 61(1):12.
19. Marincola F.M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 2003, 24(6):335.
20. Marques R.B., Erkens-Schulze S., de Ridder C.M., Hermans K.G., Waltering K., Visakorpi T., Trapman J., Romijn J.C., van Weerden W.M., Jenster G. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int. J. Cancer 2005, 117(2):221.
21. Milowsky M.I., Nanus D.M., Kostakoglu L., Sheehan C.E., Vallabhajosula S., Goldsmith S.J., Ross J.S., Bander N.H. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 2007, 25(5):540.
22. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and Rosenberg, S.A., 2010. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Mol Ther. 18 (4), 843.
23. Paulson D.F., Moul J.W., Robertson J.E., Walther P.J. Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. J. Urol. 1990, 143(6):1178.
24. Pinthus J.H., Waks T., Kaufman-Francis K., Schindler D.G., Harmelin A., Kanety H., Ramon J., Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 2003, 63(10):2470.
25. Schaft N., Lankiewicz B., Gratama J.W., Bolhuis R.L., Debets R. Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT. J. Immunol. Meth. 2003, 280(1-2):13.
26. Sinha A.A., Blackard C.E., Seal U.S. A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma. Cancer 1977, 40(6):2836.
27. Uemura H., Nakagawa Y., Yoshida K., Saga S., Yoshikawa K., Hirao Y., Oosterwijk E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer 1999, 81(4):741.
28. Van de Griend R.J., Van Krimpen B.A., Bol S.J., Thompson A., Bolhuis R.L. Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J. Immunol. Meth. 1984, 66(2):285.
29. Weijtens M.E., Willemsen R.A., Valerio D., Stam K., Bolhuis R.L. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J. Immunol. 1996, 157(2):836.
30. Weijtens M.E., Willemsen R.A., Hart E.H., Bolhuis R.L. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 1998, 5(9):1195.
31. Willemsen R.A., Debets R., Chames P., Bolhuis R.L. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol. 2003, 64(1):56.